Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Ensysce Biosciences, Inc. (Nasdaq: ENSC) filed this Current Report on Form 8-K on February 14, 2024, regarding events occurring on February 12 and 13, 2024. The filing details a material definitive agreement involving the inducement of existing warrant holders to exercise their warrants at a reduced price in exchange for new warrant issuances.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.7 million from the exercise of existing warrants.
- Shares Exercised: 3,601,752 shares of Common Stock.
- Reduced Exercise Price: $1.31 per share (reduced from the original $3.637 per share).
- New Warrant Issuance:
- Series A Warrants: 3,601,752 shares; Exercise price $1.06; Term 18 months.
- Series B Warrants: 3,601,752 shares; Exercise price $1.06; Expiry May 12, 2028.
- Placement Agent Fees: $200,000 cash fee, plus $20,000 for non-accountable expenses, $30,000 for counsel fees, and $15,950 for clearing fees.
- Placement Agent Warrants: 252,123 shares (7.0% of aggregate placed); Exercise price $1.6375; Expiry May 12, 2028.
Material Changes and Agreements
The Company entered into an Inducement Letter Agreement to facilitate the cash exercise of existing warrants. This transaction required a waiver of restrictions under a Securities Purchase Agreement (SPA) dated October 23, 2023. As a condition of the waiver, the Company must fully repay the notes issued under the SPA with a premium following the closing of this transaction. The filing does not provide specific values for the outstanding notes or the premium amount.
Outlook, Restrictions, and Risks
- Issuance Restrictions: The Company agreed not to issue Common Stock or equivalents or file other registration statements until the earlier of 90 days after closing or the day following 10 consecutive trading days where the closing price equals or exceeds $1.57 per share.
- Variable Rate Transaction Ban: The Company cannot effect any Variable Rate Transaction for one year after the closing date, subject to exceptions.
- Registration: The Company agreed to file a Resale Registration Statement for the New Warrant Shares as soon as practicable.
- Unregistered Sales: The Series A, Series B, and Placement Agent Warrants were issued pursuant to Section 4(a)(2) of the Securities Act and are not registered.
Key Facts for Investor Verification
- Verify the total amount of debt repayment required under the October 23, 2023 SPA waiver, including the specific premium amount.
- Confirm the dilution impact of the 7.2 million new warrant shares (Series A and B) and 252,123 placement agent warrants.
- Monitor the stock price relative to the $1.57 threshold to determine when the issuance lock-up period expires.
- Review the timing of the Resale Registration Statement filing to assess liquidity for new warrant holders.